RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (original) (raw)

Nature volume 478, pages 524–528 (2011)Cite this article

Subjects

Abstract

Epigenetic pathways can regulate gene expression by controlling and interpreting chromatin modifications. Cancer cells are characterized by altered epigenetic landscapes, and commonly exploit the chromatin regulatory machinery to enforce oncogenic gene expression programs1. Although chromatin alterations are, in principle, reversible and often amenable to drug intervention, the promise of targeting such pathways therapeutically has been limited by an incomplete understanding of cancer-specific dependencies on epigenetic regulators. Here we describe a non-biased approach to probe epigenetic vulnerabilities in acute myeloid leukaemia (AML), an aggressive haematopoietic malignancy that is often associated with aberrant chromatin states2. By screening a custom library of small hairpin RNAs (shRNAs) targeting known chromatin regulators in a genetically defined AML mouse model, we identify the protein bromodomain-containing 4 (Brd4) as being critically required for disease maintenance. Suppression of Brd4 using shRNAs or the small-molecule inhibitor JQ1 led to robust antileukaemic effects in vitro and in vivo, accompanied by terminal myeloid differentiation and elimination of leukaemia stem cells. Similar sensitivities were observed in a variety of human AML cell lines and primary patient samples, revealing that JQ1 has broad activity in diverse AML subtypes. The effects of Brd4 suppression are, at least in part, due to its role in sustaining Myc expression to promote aberrant self-renewal, which implicates JQ1 as a pharmacological means to suppress MYC in cancer. Our results establish small-molecule inhibition of Brd4 as a promising therapeutic strategy in AML and, potentially, other cancers, and highlight the utility of RNA interference (RNAi) screening for revealing epigenetic vulnerabilities that can be exploited for direct pharmacological intervention.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications—miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457–469 (2010)
    Article CAS Google Scholar
  2. Chen, J., Odenike, O. & Rowley, J. D. Leukaemogenesis: more than mutant genes. Nature Rev. Cancer 10, 23–36 (2010)
    Article CAS Google Scholar
  3. Gilliland, D. G., Jordan, C. T. & Felix, C. A. The molecular basis of leukemia. Hematology (Am. Soc. Hematol. Educ. Program) 80–97 (2004)
  4. Figueroa, M. E. et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13–27 (2010)
    Article CAS PubMed PubMed Central Google Scholar
  5. Dick, J. E. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008)
    Article CAS PubMed Google Scholar
  6. Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S. & Liu, J. M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA 95, 10860–10865 (1998)
    Article ADS CAS PubMed PubMed Central Google Scholar
  7. Krivtsov, A. V. et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14, 355–368 (2008)
    Article CAS PubMed PubMed Central Google Scholar
  8. Delhommeau, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009)
    Article PubMed Google Scholar
  9. Ley, T. J. et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424–2433 (2010)
    Article CAS PubMed PubMed Central Google Scholar
  10. Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nature Biotechnol. 29, 79–83 (2011)
    Article CAS Google Scholar
  11. Yokoyama, A. & Cleary, M. L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14, 36–46 (2008)
    Article CAS PubMed PubMed Central Google Scholar
  12. Yokoyama, A. et al. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123, 207–218 (2005)
    Article CAS PubMed Google Scholar
  13. Wu, S. Y. & Chiang, C. M. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J. Biol. Chem. 282, 13141–13145 (2007)
    Article CAS PubMed Google Scholar
  14. French, C. A. et al. BRD4–NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 63, 304–307 (2003)
    CAS PubMed Google Scholar
  15. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010)
    Article ADS CAS PubMed PubMed Central Google Scholar
  16. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119–1123 (2010)
    Article ADS CAS PubMed PubMed Central Google Scholar
  17. Zuber, J. et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877–889 (2009)
    Article CAS PubMed PubMed Central Google Scholar
  18. Somervaille, T. C. & Cleary, M. L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257–268 (2006)
    Article CAS PubMed Google Scholar
  19. Krivtsov, A. V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006)
    Article ADS CAS PubMed Google Scholar
  20. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005)
    Article ADS CAS PubMed PubMed Central Google Scholar
  21. Somervaille, T. C. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009)
    Article CAS PubMed PubMed Central Google Scholar
  22. Kim, J. et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143, 313–324 (2010)
    Article CAS PubMed PubMed Central Google Scholar
  23. Wong, P. et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 70, 3833–3842 (2010)
    Article CAS PubMed PubMed Central Google Scholar
  24. Jang, M. K. et al. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523–534 (2005)
    Article CAS PubMed Google Scholar
  25. Yang, Z., He, N. & Zhou, Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell. Biol. 28, 967–976 (2008)
    Article CAS PubMed Google Scholar
  26. Schuhmacher, M. et al. The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res. 29, 397–406 (2001)
    Article CAS PubMed PubMed Central Google Scholar
  27. Schmidt, M., Nazarov, V., Stevens, L., Watson, R. & Wolff, L. Regulation of the resident chromosomal copy of c-myc by c-Myb is involved in myeloid leukemogenesis. Mol. Cell. Biol. 20, 1970–1981 (2000)
    Article CAS PubMed PubMed Central Google Scholar
  28. Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008)
    Article ADS CAS PubMed PubMed Central Google Scholar
  29. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199–207 (1999)
    Article CAS PubMed Google Scholar
  30. Wilson, A. et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 18, 2747–2763 (2004)
    Article CAS PubMed PubMed Central Google Scholar
  31. Zuber, J. et al. An integrated approach to dissecting oncogene addiction implicates a Myb coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 10.1101/gad.1726911 (in the press)
  32. Taylor, J., Schenck, I., Blankenberg, D. & Nekrutenko, A. Using galaxy to perform large-scale interactive data analyses in Curr. Protoc. Bioinformatics Ch. 10, Unit 10.5. (2007)
  33. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289–1295 (2005)
    Article CAS PubMed Google Scholar
  34. Hemann, M. T. et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genet. 33, 396–400 (2003)
    Article CAS PubMed Google Scholar
  35. Wei, J. et al. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell 13, 483–495 (2008)
    Article CAS PubMed PubMed Central Google Scholar
  36. Wunderlich, M. & Mulloy, J. C. Model systems for examining effects of leukemia-associated oncogenes in primary human CD34+ cells via retroviral transduction. Methods Mol. Biol. 538, 263–285 (2009)
    Article CAS PubMed PubMed Central Google Scholar
  37. Bennett, J. M. et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33, 451–458 (1976)
    Article CAS PubMed Google Scholar
  38. Bennett, J. M. et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann. Intern. Med. 103, 620–625 (1985)
    Article CAS PubMed Google Scholar
  39. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951 (2009)
    Article CAS PubMed Google Scholar
  40. Reich, M. et al. GenePattern 2.0. Nature Genet. 38, 500–501 (2006)
    Article CAS PubMed Google Scholar
  41. Steger, D. J. et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 28, 2825–2839 (2008)
    Article CAS PubMed PubMed Central Google Scholar
  42. Zeng, P. Y., Vakoc, C. R., Chen, Z. C., Blobel, G. A. & Berger, S. L. In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques 41, 694–698 (2006)
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We thank B. Ma, S. Muller and M. Weissenboeck for technical assistance; J. Simon, E. Earl and L. Bianco for support with mouse work; C. dos Santos for assistance with LSK FACS analysis; S. Hearn for microscopy support; G. Hannon, K. Chang, and E. Hodges for shRNA technology support; A. Gordon and M. Hammell for bioinformatics support; L. Dow for assistance with mouse pathology sample preparation; and G. Blobel for comments on the manuscript. We thank the Don Monti Memorial Research Foundation and Laurie Strauss Leukemia Foundation for research support. J.Z. was supported by a research fellowship from the German Research Foundation (DFG) and by the Andrew Seligson Memorial Clinical Fellowship at CSHL; A.R.R. was supported by an NIH traineeship and the Barbara McClintock fellowship; J.E.B and J.Q. are supported by the Damon-Runyon Cancer Research Foundation and Smith Family Foundation. P.B. is supported by a Damon Runyon-Lilly Clinical Investigator Award and a Leukemia and Lymphoma Society (LLS) Translational Research Program Grant, and is an LLS Scholar in Clinical Research. S.W.L. is supported by a Specialized Center of Research (SCOR) grant from the Leukemia and Lymphoma Society of America, a Cancer Target Discovery and Development (CTD2) grant from the National Cancer Institute, and by the Howard Hughes Medical Institute; C.R.V., J.S. and E.W. are supported by the CSHL President’s Council and the SASS Foundation for Medical Research.

Author information

Author notes

  1. Johannes Zuber and Junwei Shi: These authors contributed equally to this work.

Authors and Affiliations

  1. Cold Spring Harbor Laboratory, 1 Bungtown Road, Cold Spring Harbor, 11724, New York, USA
    Johannes Zuber, Junwei Shi, Eric Wang, Amy R. Rappaport, Meredith J. Taylor, Christopher Johns, Agustin Chicas, Scott W. Lowe & Christopher R. Vakoc
  2. Research Institute of Molecular Pathology (IMP), Dr. Bohr-Gasse 7, A-1030 Vienna, Austria,
    Johannes Zuber
  3. Molecular and Cellular Biology Program, Stony Brook University, Stony Brook, 11794, New York, USA
    Junwei Shi
  4. Watson School of Biological Sciences, 1 Bungtown Road, Cold Spring Harbor, 11724, New York, USA
    Amy R. Rappaport & Scott W. Lowe
  5. Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, A-1090 Vienna, Austria,
    Harald Herrmann & Peter Valent
  6. Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, 21231, Maryland, USA
    Edward A. Sison, Daniel Magoon & Patrick Brown
  7. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA,
    Jun Qi & James E. Bradner
  8. Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, A-1090 Vienna, Austria,
    Katharina Blatt & Peter Valent
  9. Division of Experimental Hematology and Cancer Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, 45229, Ohio, USA
    Mark Wunderlich & James C. Mulloy
  10. Department of Laboratory Medicine, University of California at San Francisco, San Francisco, 94143, California, USA
    Scott C. Kogan
  11. Howard Hughes Medical Institute, 1 Bungtown Road, Cold Spring Harbor, 11724, New York, USA
    Scott W. Lowe

Authors

  1. Johannes Zuber
    You can also search for this author inPubMed Google Scholar
  2. Junwei Shi
    You can also search for this author inPubMed Google Scholar
  3. Eric Wang
    You can also search for this author inPubMed Google Scholar
  4. Amy R. Rappaport
    You can also search for this author inPubMed Google Scholar
  5. Harald Herrmann
    You can also search for this author inPubMed Google Scholar
  6. Edward A. Sison
    You can also search for this author inPubMed Google Scholar
  7. Daniel Magoon
    You can also search for this author inPubMed Google Scholar
  8. Jun Qi
    You can also search for this author inPubMed Google Scholar
  9. Katharina Blatt
    You can also search for this author inPubMed Google Scholar
  10. Mark Wunderlich
    You can also search for this author inPubMed Google Scholar
  11. Meredith J. Taylor
    You can also search for this author inPubMed Google Scholar
  12. Christopher Johns
    You can also search for this author inPubMed Google Scholar
  13. Agustin Chicas
    You can also search for this author inPubMed Google Scholar
  14. James C. Mulloy
    You can also search for this author inPubMed Google Scholar
  15. Scott C. Kogan
    You can also search for this author inPubMed Google Scholar
  16. Patrick Brown
    You can also search for this author inPubMed Google Scholar
  17. Peter Valent
    You can also search for this author inPubMed Google Scholar
  18. James E. Bradner
    You can also search for this author inPubMed Google Scholar
  19. Scott W. Lowe
    You can also search for this author inPubMed Google Scholar
  20. Christopher R. Vakoc
    You can also search for this author inPubMed Google Scholar

Contributions

J.Z., J.S. and C.R.V. designed research, performed experiments and analysed data. E.W., A.R.R. and M.J.T. performed experiments and analysed data. C.J. performed microarray experiments. A.C. assisted with shRNA library design. H.H., E.A.S., D.M., K.B., P.B. and P.V. performed experiments with primary leukaemia specimens. J.C.M. and M.W. generated and provided engineered AML lines. S.C.K. performed histological analysis. J.Q. and J.E.B. designed research and synthesized and supplied JQ1. J.Z., S.W.L. and C.R.V. co-wrote the paper. S.W.L. and C.R.V. supervised the research.

Corresponding authors

Correspondence toScott W. Lowe or Christopher R. Vakoc.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains sequences of primers used in this study and Supplementary Figures 1-26 with legends. (PDF 24057 kb)

Supplementary Table 1

This file contains the sequences and primary screening performance of the custom shRNA library, including 1094 negative control shRNAs (designated PC and NC, respectively). shRNAs were designated by the number of the first nucleotide of the 22-nt target site in the mRNA transcript at the time of design. Provided are sequences of the 22-nt guide strands as well as a 97-nt oligonucleotides serving as templates for shRNA cloning using PCR. The relative abundance of each shRNA in the pool at the start (T0) and the endpoint (T14) of the screen is provided as normalized deep sequencing reads in two independent replicates (A and B). The relative change in representation is calculated as the ratio of reads in T14 compared to reads in T0 for both replicates. Only shRNAs with sufficient read numbers for evaluating depletion (>500 reads in both replicates, 1072 shRNAs = 97%) were analyzed. Scorers were defined as genes for which at least 2 shRNAs showed more than 20fold (T14/T0 < 0.05) in both replicates. (XLS 444 kb)

Supplementary Table 2

This file contains the gene sets used for Gene Set Enrichment Analysis (GSEA). Mouse genesets were obtained were converted into human gene names using bioDBNet dbWalk (http://biodbnet.abcc.ncifcrf.gov/db/dbWalk.php) or manually using the NCBI database. (XLS 84 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Zuber, J., Shi, J., Wang, E. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.Nature 478, 524–528 (2011). https://doi.org/10.1038/nature10334

Download citation

Editorial Summary

Brd4 target in acute myeloid leukaemia

In an RNAi screen targeting chromatin regulators, Vakoc and colleagues find that maintenance of acute myeloid leukaemia (AML) requires Brd4, which binds to acetylated histones to influence gene transcription. Brd4 regulates expression of the oncogene Myc and a Myc-driven gene-expression program that permits leukaemia cells to self-renew. JQ1, a small molecule that inhibits Brd4 function, has anti-leukaemic effects in a mouse model and inhibits the proliferation of primary human AML cells, suggesting a therapeutic approach in patients with AML.